Assessing Thrombotic Risk in Patients with HR+/HER2- Breast Cancer Receiving CDK4/6 Inhibitors: Insights from Real-World Data from the Middle East
This study shows a higher incidence of thrombotic events in real-world settings than clinical trials, emphasizing the need for risk assessment and possible thromboprophylaxis in patients receiving CDK4/6 inhibitors. Future risk assessment tools needed to be applied in breast cancer patients receiving CDK4/6 inhibitors and risk of developing thrombosis.
Authors
- Hatoon Bakhribah
- Sadal Refae
- Nafisa Abdelhafiez
- Maha AlDoughaim (ORCID: https://orcid.org/0009-0008-7229-9474)
- Tariq Alqahtani (ORCID: https://orcid.org/0009-0007-1094-6835)
- Saleh Alyousef
- Rawan Abu Alnasr
- Ibtihal Althumali
- Bandar Aldawish
- A. Alanazi
- Lama Alfehaid
- Sultan Aljardan
- Nada Alsuhebany
- Mohammed Alzahrani
Institutions
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Fahd Medical City (SA)
- King Abdulaziz Medical City (SA)
- King Abdullah International Medical Research Center (SA)
- National Guard Health Affairs (SA)
Publication Details
- Journal
- Breast Cancer Targets and Therapy
- Published
- 2026-01-01
- DOI
- https://doi.org/10.2147/bctt.s554024
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- King Fahad Medical City
- King Abdullah International Medical Research Center